Background
==========

The first-generation hetastarch remains the only hydroxyethyl starch (HES) available for volume substitution in the United States despite its controversial safety profile. The safety and efficacy of a new HES, Voluven^®^, was assessed in this investigation.

Patients and methods
====================

After local IRB approval and signed, written informed consent, 100 adult patients scheduled for major orthopedic surgery were randomly allocated to receive 6% HES 130/0.4 (Voluven^®^, *n*= 49) or 6% HES 450/0.7 (hetastarch, *n*= 51) for intraoperative volume replacement in a double-blind fashion guided by a predefined algorithm that included CVP-guided therapy. HES volume served as the primary efficacy variable. Safety variables were: calculated total red blood cell (RBC) loss, minimum factor VIII activity and vW factor concentration between the end of surgery and 2 hours later, laboratory parameters, and adverse events through POD 28. The treatment groups were compared for equivalence in efficacy and superiority of HES 130/0.4 in safety.

Results
=======

Demographic data and other baseline characteristics of the treatment groups were similar. Mean infused HES volumes were equivalent between groups (1615 ± 778 ml for HES 130/0.4 and 1584 ± 958 ml for HES 450/0.7). Primary safety results are presented in Table [1](#T1){ref-type="table"} (mean ± standard deviation; \**P*\< 0.05). Three coagulopathies were reported as serious adverse events in the HES 450/0.7 group (\> 3 l HES 450/0.7 administered in all cases). No coagulopathies were reported for HES 130/0.4.

                RBC loss (l)   Factor VIII (%) with \>1 l HES   vW factor (%) with \>1 l HES   RBC use (ml/kg)
  ------------- -------------- -------------------------------- ------------------------------ -----------------
  HES 130/0.4   1.17 ± 0.63    88.7 ± 55.7                      89.2 ± 40.4                    8.0 ± 6.4
  HES 450/0.7   1.31 ± 0.84    65.9 ± 39.4\*                    71.5 ± 36.9\*                  13.8 ± 12.9\*

Conclusion
==========

HES 130/0.4 (Voluven^®^) and HES 450/0.7 (hetastarch) are equally effective volume expanders in major orthopedic surgery. HES 130/0.4, however, demonstrated a more favorable safety profile including preservation of critical coagulation factors and reduced requirement for transfusion of blood products.
